T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Douglas Elliman
DOUG
$183M
| $484K | ﹤0.01% |
204,007
| – | – |
|
2402
Emergent Biosolutions
EBS
$230M
| $482K | ﹤0.01% |
38,983
-1,458
| -4% | -$15.6K |
|
2403
NerdWallet
NRDS
$639M
| $482K | ﹤0.01% |
35,545
+2,447
| +7% | +$32K |
|
|
INVX
2404
Innovex International
INVX
$2.15B
| $482K | ﹤0.01% |
22,021
+1,688
| +8% | +$35.2K |
|
2405
Mitek Systems
MITK
$853M
| $478K | ﹤0.01% |
45,261
+3,316
| +8% | +$31.3K |
|
2406
Aveanna Healthcare
AVAH
$2.46B
| $477K | ﹤0.01% |
58,262
+12,992
| +29% | +$117K |
|
2407
Kura Oncology
KURA
$896M
| $476K | ﹤0.01% |
45,727
+3,768
| +9% | +$39.5K |
|
2408
Sixth Street Specialty
TSLX
$1.82B
| $476K | ﹤0.01% |
21,905
+968
| +5% | +$21.1K |
|
2409
Central Pacific Financial
CPF
$1B
| $474K | ﹤0.01% |
15,201
+655
| +5% | +$19.7K |
|
|
MAGN
2410
Magnera Corp
MAGN
$433M
| $474K | ﹤0.01% |
31,277
+13,576
| +77% | +$157K |
|
2411
Forestar Group
FOR
$1.51B
| $471K | ﹤0.01% |
19,092
+1,293
| +7% | +$33K |
|
2412
Forward Air
FWRD
$682M
| $470K | ﹤0.01% |
18,795
-6,300
| -25% | -$142K |
|
2413
Kopin
KOPN
$898M
| $470K | ﹤0.01% |
200,518
+9,921
| +5% | +$28.6K |
|
2414
PC Connection
CNXN
$2.04B
| $469K | ﹤0.01% |
8,112
+618
| +8% | +$36.8K |
|
2415
Horizon Bancorp
HBNC
$1.05B
| $469K | ﹤0.01% |
27,624
+4,832
| +21% | +$80K |
|
2416
Levi Strauss
LEVI
$8.63B
| $469K | ﹤0.01% |
22,608
| – | – |
|
|
LAND
2417
Gladstone Land Corp
LAND
$358M
| $468K | ﹤0.01% |
51,139
+19,050
| +59% | +$174K |
|
2418
iRadimed
IRMD
$1.11B
| $466K | ﹤0.01% |
4,782
+458
| +11% | +$39.3K |
|
2419
Opko Health
OPK
$1.04B
| $463K | ﹤0.01% |
367,191
+23,905
| +7% | +$33.3K |
|
|
BAND
2420
Bandwidth Inc
BAND
$1.74B
| $462K | ﹤0.01% |
29,896
+2,250
| +8% | +$34.1K |
|
2421
Daktronics
DAKT
$988M
| $462K | ﹤0.01% |
23,351
+1,764
| +8% | +$33.7K |
|
2422
Clearwater Paper
CLW
$354M
| $461K | ﹤0.01% |
26,446
+4,812
| +22% | +$88.7K |
|
|
SFD
2423
Smithfield Foods
SFD
$8.85B
| $461K | ﹤0.01% |
20,604
+1,320
| +7% | +$29K |
|
2424
Myriad Genetics
MYGN
$303M
| $459K | ﹤0.01% |
74,542
+14,268
| +24% | +$103K |
|
|
SERV
2425
Serve Robotics
SERV
$428M
| $458K | ﹤0.01% |
44,084
+19,271
| +78% | +$231K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.